These innovative molecules represent a significant advancement in the treatment of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose https://kaleeesk560188.ttblogs.com/18991373/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide